GlassScriptPhysician profile
Mhd A Alsaka
NPI 1184880049
$1,067.41
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $362 · 2021: $434 · 2022: $36.80 · 2024: $23.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $288.61 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $181.77 | 2020-2021 | |
| Vifor Pharma, INC. | $135.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $113.28 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $102.01 | 2020-2021 | |
| Amgen INC. | $98.89 | 2021 | |
| Daiichi Sankyo INC. | $73.21 | 2020-2022 | |
| Akebia Therapeutics INC | $23.80 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.72 | 2021 | |
| Mallinckrodt Enterprises LLC | $15.78 | 2019 | |
| Pharmacosmos Therapeutics INC. | $13.99 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mhd Alsaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.